Skip to main content

Author: Customer Service

Forge Nano, U.S. Advanced Manufacturing Leader for AI-Era Chips and Defense Batteries, to List on NASDAQ through Merger with Archimedes Tech SPAC Partners II Co.

Advanced Manufacturing Platform Supporting Critical Industries: U.S. advanced manufacturing company enabling next-generation semiconductors and batteries through its proprietary Atomic Layer Deposition (“ALD”) nanocoating platform, backed by 200+ patents and a combination of LOIs, pipeline of $2B+, $84M binding off-take agreements Multi-Phase Growth Plan with Significant Scale Opportunity: A three-phase growth plan targeting an estimated $359 billion+ expected addressable market by 2034, supported by Tier-1 strategic battery partnership and a $100 million U.S. Department of Energy grant Validated by Global Industry Leaders and Policy Tailwinds: Strategic equity investors include GM Ventures, Hanwha Aerospace, Volkswagen, Air Liquide and LG Technology Ventures. Forge Nano technology already deployed in Spire Global satellites launched...

Continue reading

Bonaventure Closes on Royal Pointe Apartments in Virginia Beach, Expanding Multifamily Value-Add Portfolio

ALEXANDRIA, Va., April 21, 2026 (GLOBE NEWSWIRE) — Bonaventure, an operator-led multifamily real estate investment firm with approximately $2.8 billion in assets under management (AUM), announced the closing of Royal Pointe Apartments, a 208-unit multifamily community in Virginia Beach, VA. The $39.5M acquisition was completed through Bonaventure Multifamily Income Trust (BMIT) and demonstrates the company’s continued focus on value-add multifamily investments across the Mid-Atlantic and Southeast regions. The transaction incorporated a combination of tax-efficient structures, including a partial 1031 exchange and a 721 exchange (UPREIT), providing flexibility and liquidity options for the investors. Bonaventure worked with Greystone to assume the property’s existing financing as part of the acquisition. “In a transitional market,...

Continue reading

NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026

Poster to be presented at the American Society for Clinical Oncology on Monday, June 1, 2026 BELTSVILLE, Md., April 21, 2026 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer and Simcere Zaiming Pharmaceutical Co., Ltd., (Simcere) an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096), today announced a poster will be presented at ASCO 2026 highlighting Phase 1 data for SIM0505 in the treatment of solid tumors. ASCO 2026 is being held May 29 – June 2 in Chicago, Illinois. SIM0505 is an investigational antibody drug conjugate (ADC) targeting Cadherin-6 (CDH6) with a proprietary topoisomerase 1 inhibitor (TOPOi) payload. “We are...

Continue reading

Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting

DOYLESTOWN, Pa., April 21, 2026 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced the acceptance of an abstract “Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)” at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to take place May 29 – June 2, 2026, in Chicago, IL.  Presentation Details:Title: Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)Presenting author: Shiraj Sen, MD. PhD., NEXT Oncology Dallas, TXSession: Poster...

Continue reading

Leads Biolabs’ PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Enters Phase Ⅱ Trial with First Patient Dosing in Gastric Cancer, Pioneering Enhanced Immunotherapy Combination Strategies

NANJING, China, April 21, 2026 (GLOBE NEWSWIRE) — Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that the first patient has been successfully dosed in a phase Ⅱ clinical study evaluating Opamtistomig (LBL-024), the company’s core investigational PD-L1/4-1BB bispecific antibody, for the first-line treatment of locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. Early symptoms of gastric cancer are often subtle and easily overlooked, leading to most patients being diagnosed at an advanced stage and facing a generally poor prognosis. PD-1 antibody combined with chemotherapy is recommended as the first-line treatment for advanced disease, with median progression-free survival (PFS) at only 7 months and median overall survival (OS) ranging from 13...

Continue reading

SoundHound AI To Acquire LivePerson, Combining Proprietary Voice Agentic AI and Digital Messaging to Create a World Leading End-to-End Omnichannel Conversational AI Platform

Transaction results in one of the most comprehensive enterprise customer footprints in the conversational AI sector, including 25 of the Fortune 100 Combined company expects a $500M revenue opportunity, accelerated path to profitability, strong balance sheet, and no debtSANTA CLARA, Calif. and NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) — SoundHound AI, Inc. (Nasdaq: SOUN), a global leader in voice and conversational AI, and LivePerson (Nasdaq: LPSN), a pioneer in enterprise conversational AI serving hundreds of enterprise and mid-market brands, today announced they have entered into a definitive agreement under which SoundHound will acquire LivePerson. The combination unifies SoundHound’s industry-leading voice and agentic AI platform with LivePerson’s digital engagement capabilities, which power one billion customer messages...

Continue reading

Churchill Downs Incorporated Announces Definitive Agreement to Acquire Preakness Intellectual Property Rights

LOUISVILLE, Ky., April 21, 2026 (GLOBE NEWSWIRE) — Churchill Downs Incorporated (Nasdaq: CHDN) (the “Company”, “CDI”, “we”) announced today that it has entered into a definitive agreement to acquire the intellectual property, including all trademarks and associated rights, of the Preakness Stakes and Black-Eyed Susan Stakes (the “Preakness IP Rights”) from 1/ST Maryland LLC, an affiliate of 1/ST Racing, for a purchase price of $85 million, subject to customary closing conditions (the “Transaction”). The Preakness IP Rights are subject to an Exclusive License Agreement pursuant to which CDI will license to the State of Maryland the intellectual property rights necessary to conduct the running of the Preakness Stakes and Black-Eyed Susan Stakes in exchange for an annual fee. The Preakness Stakes, first run in 1873, is the second...

Continue reading

Multitude AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements

Multitude AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements21. Apr 2026 / 15:00 CET/CEST, transmitted by GlobeNewswire.The issuer is solely responsible for the content of this announcement.Multitude AG hereby announces that the following financial reports shall be disclosed:Report type: Quarterly report and quarterly/interim statementDate of disclosure: 21.05.2026Language: English Address: https://www.multitude.com/investors/results-reports-and-publications/2026End of messageGlobeNewsWire Distribution Services include regulatory announcements, financial/corporate news and press releases.Archive at www.globenewswire.comLanguageEnglishCompanyMultitude AG...

Continue reading

White River Bancshares Co. Reports Net Income of $3.4 million, or $1.38 Per Diluted Share, for the First Quarter of 2026

FAYETTEVILLE, Ark., April 21, 2026 (GLOBE NEWSWIRE) — White River Bancshares Company (OTCQX: WRIV) (the “Company”), the holding company for Signature Bank of Arkansas (the “Bank”), today reported net income of $3.38 million, or $1.38 per diluted share, in the first quarter of 2026, compared to $4.36 million, or $1.78 per diluted share, in the fourth quarter of 2025, and $2.63 million, or $1.07 per diluted share, in the first quarter of 2025. “Our first quarter results reflect strong growth and solid performance across the bank, a direct outcome of the genuine relationships we build with our customers and communities,” said Gary Head, Chief Executive Officer. “Community banking is about earning trust over time through authentic customer service, and that mentality drives everything we do. Our bankers deliver thoughtful solutions...

Continue reading

SunCar Wins Major Bid to Manage Agricultural Bank of China’s Concierge Chauffeur Services

NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) — SunCar Technology Group Inc. (the “Company” or “SunCar”) (NASDAQ: SDA), a leader in digitalizing auto insurance and services in China, has won the contract to manage all concierge chauffeur services for the Agricultural Bank of China (“AgBank”). AgBank is generally considered the second-largest bank in the world in terms of total assets. AgBank is consolidating its concierge chauffeur services on SunCar’s management platform to improve customer experience and rationalize costs. SunCar’s platform will manage these services for three groups: Private Banking Department, Personal Banking, and the Credit Card Center. The contract has a term of three years and a total estimated value of $50 million for the Company over the length of the contract. The successful bid included...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.